Nicox S.A.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 23, 2026The maintenance fee for Quinone based nitric oxide donating compounds (US 9,061,962) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 1 fee due Jan 14, 2027The maintenance fee for Quinone based nitric oxide donating compounds (US 9,079,821) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Nitric Oxide Releasing Phosphodiesterase Type 5 Inhibitor (US 11,980,618) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,754,772 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,067,414 | Nitric Oxide Enhancing Prostaglandin Compounds, Compositions and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,691,869 | Pharmaceutical formulation of nitrooxyderivatives of NSAIDs In force · From the USPTO record | In force | From the USPTO record | |
| US 8,003,811 | Nitric oxide donor compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 8,058,467 | Prostaglandin derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 8,101,658 | Nitric oxide donating prostamides In force · From the USPTO record | In force | From the USPTO record | |
| US 9,061,962 | Quinone based nitric oxide donating compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,079,821 | Quinone based nitric oxide donating compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,446,015 | Quinone based nitric oxide donating compounds for ophthalmic use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,220,055 | Composition Effective Against Viral Conjunctivitis In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 2 patents in force now held by others · 120 lapsed for an unpaid fee · 21 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 1 abandoned · 35 no status recorded